| (Values in U.S. Thousands) | Apr, 2026 | Jan, 2026 | Jul, 2025 | Apr, 2025 | Jan, 2025 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -3,228 | -2,334 | -2,197 | -4,074 | -3,777 |
| Net Income Growth | -38.28% | -6.24% | +46.06% | -7.85% | +33.68% |
Sernova Biotherapeutics Inc (SVA.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Sernova Biotherapeutics Inc is a clinical-stage biotechnology company focused on advancing regenerative medicine for the treatment of chronic diseases. The Company's primary asset is its proprietary Cell Pouch, a bio-hybrid organ system designed to enhance the delivery of cell therapy by replicating natural body functions. The Cell Pouch creates a vascularized, organ-like environment that promotes the longevity and functionality of therapeutic cells and ensures containment for retrievability.
Fiscal Year End Date: 10/31